Last reviewed · How we verify
Primacor (Milrinone Lactate)
Primacor (Milrinone Lactate) is a phosphodiesterase 3 inhibitor, a small molecule drug developed by Sanofi Aventis US, targeting the phosphodiesterase 3 enzyme. It is used to treat decompensated cardiac failure and was FDA approved in 1987. Primacor is now off-patent with 16 generic manufacturers available. The drug has a short half-life of 0.8 hours and high bioavailability of 86%. Key safety considerations include its potential to cause hypotension and arrhythmias.
At a glance
| Generic name | Milrinone Lactate |
|---|---|
| Sponsor | Sanofi |
| Drug class | Phosphodiesterase 3 Inhibitor |
| Target | Phosphodiesterase 3 |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
- Acute decompensated heart failure
Common side effects
- Ventricular arrhythmias
- Ventricular ectopic activity
- Nonsustained ventricular tachycardia
- Sustained ventricular tachycardia
- Ventricular fibrillation
- Supraventricular arrhythmias
- Hypotension
- Angina/chest pain
- Headaches
- Hypokalemia
- Tremor
- Thrombocytopenia
Key clinical trials
- Effect of Topically-applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow (PHASE3)
- Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage (PHASE3)
- Comparison of Milrinone and Epinephrine on TAPSE (NA)
- Cerebral Oxygen Saturation Monitoring In Cardiac Surgery (COSMICS) (NA)
- Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
- Milrinone in Congenital Diaphragmatic Hernia (PHASE2)
- Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation (PHASE2)
- Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Primacor CI brief — competitive landscape report
- Primacor updates RSS · CI watch RSS
- Sanofi portfolio CI